Compare McKesson Corporation (MCK) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Okta, Inc. — how do they compare? McKesson Corporation trades at $887.34 (market cap $105.14B), while Okta, Inc. trades at $149.65 (market cap $26.13B). The key difference: McKesson Corporation is far larger — about 4× Okta, Inc.'s market cap, and McKesson Corporation pays a 0.42% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals.
| MCK | OKTA | |
|---|---|---|
Market Cap | $105.14B | $26.13B |
Sector | Health | Technology |
52-Week High | $995.69 | $154.62 |
52-Week Low | $659.01 | $62.93 |
Enterprise Value | $111.67B | $23.95B |
Dividend Yield | 0.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $879.87, up 1.18% today, with strong momentum from recent earnings beats and raised guidance. The stock shows bullish technical signals, supported by robust revenue growth and solid cash flow generation. Recent news highlights strength in specialty drugs and oncology, driving positive sentiment.
Outlook remains favorable with a consensus price target of $990.67, though thin profit margins and high liabilities pose risks. Continued execution on growth initiatives and cost discipline are key for sustained upside, while macroeconomic pressures and competitive dynamics require monitoring.
Okta trades at $150.04, down 0.48% today, near its pivot point of $150 with bullish moving averages but overbought RSI signals. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.91 exceeding expectations. Revenue growth is robust, rising to $2.61B in 2025, while the firm achieved GAAP profitability with net income of $28M, a significant turnaround from prior losses. Recent news highlights Okta's acquisition of Permiso Security to enhance AI-driven identity threat detection, positioning it in the expanding cybersecurity market.
Outlook is positive with analyst consensus at Buy (72.55%) and a $129.71 price target, though current price exceeds this. Opportunities include sustained revenue growth and margin expansion, while risks involve high valuation multiples (P/E 108.93) and competitive pressure from Microsoft. Institutional activity shows mixed signals, with some funds increasing stakes amid the stock's 55.6% YTD gain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
